Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator

Toxicologic Pathology

Volumn 29, Issue 6, 2001, Pages 719-726

  Long, Gerald G ^a   Cohen, Ilene R ^a   Gries, Christian L ^a   Young, Jamie K ^a   Francis, Paul C ^a   Capen, Charles C ^b  

^a ELI LILLY AND COMPANY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Estrogen receptor; granulosa cell tumor; granulosa cells; selective estrogen receptor modulator

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL; ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; FEMALE; FISCHER 344 RAT; GRANULOSA CELL; GRANULOSA CELL TUMOR; HYPERPLASIA; OVARY TUMOR; PATHOLOGY; RAT;

CARCINOGEN; ESTRADIOL; HORMONE; LUTEINIZING HORMONE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMALS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; GRANULOSA CELL TUMOR; GRANULOSA CELLS; HORMONES; HYPERPLASIA; LUTEINIZING HORMONE; OVARIAN NEOPLASMS; PROGESTERONE; RALOXIFENE; RATS; RATS, INBRED F344; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0035523097     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/019262301753386031     Document Type: Erratum

References (34)

1. Alison RH, Capen CC, Prentice DE (1994). Neoplastic lesions of questionable signifi cance to humans. Toxicol Pathol 22: 179-186.
2. Biskind MS, Biskind GS (1944). Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 55: 176-179.
3. Blaakaer J., Djursing H., Hording U., Bennett P., Toftager-Larsen K., Bock JE, Lebech PE (1992). The pituitary-gonada l axis in women with benign or malignant ovarian tumors. Acta Endocrinol (Copenh) 127: 127-130.
4. Brambell FWR, Parkes AS, Fielding U. (1937). Changes in the ovary of the mouse following exposure to X-rays. Proc Roy Soc London Series B 101: 29-60.
5. Capen CC, Beamer WG, Tennent BJ, Stitzel KA (1995). Mechanisms of hormone-mediated carcinogenesis of the ovary in mice. Mutat Res 333: 143-151.
6. Capen CC (1996). Hormonal imbalances an mechanisms of chemical injury of the thyroid gland. In: Monographs on Pathology of Laboratory Animals Endocrine System, Jones TC, Capen CC, Mohr U (eds). Berlin, Springer, pp 217-238.
7. Cohen IR, Sims ML, Robbins MR, Laksmanan MC, Francis PC, Long GG (2000). The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice. Repro Toxicol 14: 37-44.
8. Cramer DW, Barbieri RL, Muto MG, Kelly A., Brucks JP, Harlow BL (1994). Characteristics of women with a family history of ovarian cancer. II. Follicular phase hormone levels. Cancer 74: 1318-1322.
9. Davis BJ, Maronpot RR (1996). Chemically associated toxicity and carcinogenicity of the ovary. Prog Clin Biol Res 394: 285-308.
10. Dixon D., Leininger JR, Valerio MG, Johnson AN, Stabinski LG, Frith CH (1999). Proliferative lesions of the ovary, uterus, vagina, cervix and oviduct in rats. In: Guides for Toxicologic Pathology, STP/ARP/AFIP, Washington, DC, pp 2-5.
11. Dunnett CW (1964). New tables for multiple comparisons with a control. Biometrics 20: 482-491.
12. Ekman L., Hansson E., Havu N., Carlsson E., Lundberg C. (1985). Toxicological studies on omeprazole. Scand J Gastroenterol 20 (Suppl 108): 53-69.
13. Eli Lilly and Company (1997). Evista® Package Insert. Indianapolis, IN.
14. Ettinger B., Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T., Genant HK, Christiansen C., Delmas PD, Zanchetta JR, Stakkestad J., Gluer CC, Krueger K., Cohen FJ, Eckert S., Ensrud KE, Avioli LV, Lips P., Cummings SR (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosi s treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282: 637-645.
15. Fisher B., Costantino JP, Wickerham DL, Redmond CK, Kavanah M., Cronin WM, Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388.
16. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. (1996). Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HC1, tamoxifen, estrogen, and alendronate. Bone 18: 621-627.
17. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C., Bush TL, Hoffman SC, Comstock GW (1995). Serum gonadotropin s and steroid hormones and the development of ovarian cancer. JAMA 274: 1926-1930.
18. Hoyt JA, Fisher LF, Buelke-Sam JL, Francis PC (1998). The selective estrogen receptor modulator, raloxifene: Reproductive assessments following premating exposure in female rats. Repro Toxicol 12: 233-245.
19. Korach KS (1994). Insights from the study of animals lacking functional estrogen receptor. Science 266: 1524-1527.
20. Levene H. (1960). Robust tests for equality of variances. In: Contributions to Probability and Statistics, Olkin I, Ghurye SG, Hoeffding W, Madow WG, Mann HB (eds). Stanford University Press, Stanford, CA, pp 278-292.
21. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. (1993). Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA. 90: 11162-11166.
22. McClain RM (1989). The signifi cance of hepatic microsomal enzyme induction and altered thyroid function in rats: Implications for thyroid gland neoplasia. Toxicol Pathol 17: 294-306.
23. Marchant J. (1957). The chemical induction of ovarian tumours in mice. Br J Cancer 11: 452-464.
24. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. (1992). Alphainhibin is a tumour-suppressor gene with gonadal specifi city in mice. Nature 360: 313-319.
25. Mitlak BH, Cohen FJ (1999). Selective estrogen receptor modulators: A look ahead. Drugs 57: 653-663.
26. Murphy ED, Beamer WG (1973). Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the Wx-Wu genotype. Cancer Res 33: 721-723.
27. Niswender GD, Chen CL, Midgley AR, Jr, Meites J., Ellis S. (1969). Radioimmunoassay for rat prolactin. Proc Soc Exp Biol Med 130: 793-797.
28. Risma KA, Hirshfi eld AN, Nilson JH (1997). Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology 138: 3540-3547.
29. Schering Corporation (1997). Fareston® Package Insert. Kenilworth, NJ.
30. Sato M., Rippy MK, Bryant HU (1996). Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10: 905-912.
31. Scully KM, Gleiberman AS, Lindzey J., Lubahn DB, Korach KS, Rosenfeld MG (1997). Role of estrogen receptor-alpha in the anterior pituitary gland. Mol Endocrino l 11: 674 —681.
32. Tucker MJ, Adam HK, Patterson JS (1984). Tamoxifen. In: Safety Testing of New Drugs, Laurence DR, McLean AEM, Weatherall M (eds). Academic Press, London, pp 125-161.
33. Weiss NS, Hill DA (1996). Postmenopausa l estrogens and progestogen s and the incidence of gynecologic cancer. Maturitas 23: 235-239.
34. Yang NN, Venugopala n M., Hardikar S., Glasebrook A. (1996). Identifi cation of an estrogen respons e element activated by metabolites of 17beta-estradiol and raloxifene. Science 273: 1222-1225.